321.53MMarket Cap-7574P/E (TTM)
12.380High11.920Low63.67KVolume12.380Open12.000Pre Close770.79KTurnover0.69%Turnover RatioLossP/E (Static)26.88MShares24.00052wk High1.67P/B110.58MFloat Cap11.68052wk Low--Dividend TTM9.25MShs Float24.000Historical High--Div YieldTTM3.83%Amplitude11.680Historical Low12.106Avg Price1Lot Size
Alto Neuroscience Stock Forum
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet